Pembrolizumab plus ipilimumab or placebo for metastatic non–small-cell lung cancer with PD-L1 tumor proportion score≥ 50%: randomized, double-blind phase III …
M Boyer, MAN Şendur, D Rodríguez-Abreu… - Journal of clinical …, 2021 - ascopubs.org
PURPOSE Pembrolizumab monotherapy is standard first-line therapy for metastatic non–
small-cell lung cancer (NSCLC) with programmed death ligand 1 (PD-L1) tumor proportion …
small-cell lung cancer (NSCLC) with programmed death ligand 1 (PD-L1) tumor proportion …
Pembrolizumab in patients with advanced non-small-cell lung cancer (KEYNOTE-001): 3-year results from an open-label, phase 1 study
NB Leighl, MD Hellmann, R Hui… - The Lancet …, 2019 - thelancet.com
Background The anti-programmed death 1 monoclonal antibody pembrolizumab has shown
antitumour activity and is a first-line and second-line treatment option for patients with …
antitumour activity and is a first-line and second-line treatment option for patients with …
Long-term outcomes and retreatment among patients with previously treated, programmed death-ligand 1‒positive, advanced non‒small-cell lung cancer in the …
PURPOSE In the KEYNOTE-010 study, pembrolizumab improved overall survival (OS)
versus docetaxel in previously treated, programmed death-ligand 1 (PD-L1)‒expressing …
versus docetaxel in previously treated, programmed death-ligand 1 (PD-L1)‒expressing …
KEYNOTE‐025: Phase 1b study of pembrolizumab in Japanese patients with previously treated programmed death ligand 1–positive advanced non–small‐cell lung …
M Nishio, T Takahashi, H Yoshioka… - Cancer …, 2019 - Wiley Online Library
Pembrolizumab, a humanized monoclonal antibody against programmed death 1 (PD‐1),
has been shown to improve overall survival (OS) in patients with previously treated …
has been shown to improve overall survival (OS) in patients with previously treated …
Pembrolizumab versus chemotherapy for previously untreated, PD-L1-expressing, locally advanced or metastatic non-small-cell lung cancer (KEYNOTE-042): a …
TSK Mok, YL Wu, I Kudaba, DM Kowalski, BC Cho… - The Lancet, 2019 - thelancet.com
Background First-line pembrolizumab monotherapy improves overall and progression-free
survival in patients with untreated metastatic non-small-cell lung cancer with a programmed …
survival in patients with untreated metastatic non-small-cell lung cancer with a programmed …
[HTML][HTML] LBA52 EMPOWER-Lung 1: Phase III first-line (1L) cemiplimab monotherapy vs platinum-doublet chemotherapy (chemo) in advanced non-small cell lung …
A Sezer, S Kilickap, M Gümüş… - Annals of …, 2020 - annalsofoncology.org
Background EMPOWER-Lung 1 is a multicentre, open-label, global, phase III study of
cemiplimab, an anti–PD-1, in patients (pts) with treatment-naïve stage IIIB, IIIC, or IV …
cemiplimab, an anti–PD-1, in patients (pts) with treatment-naïve stage IIIB, IIIC, or IV …
[HTML][HTML] Pembrolizumab as first-line therapy for patients with PD-L1-positive advanced non-small cell lung cancer: a phase 1 trial
Background Pembrolizumab improved survival as first-and second-line therapy compared
with chemotherapy in patients with highly programmed death ligand 1 (PD-L1) expressing …
with chemotherapy in patients with highly programmed death ligand 1 (PD-L1) expressing …
Pembrolizumab as a monotherapy or in combination with platinum-based chemotherapy in advanced non-small cell lung cancer with PD-L1 tumor proportion score …
E Dudnik, M Moskovitz, Y Rottenberg… - …, 2021 - Taylor & Francis
Both pembrolizumab (P) and combination of pembrolizumab with platinum-based
chemotherapy (PCT) represent standard 1st-line options for advanced non-small cell lung …
chemotherapy (PCT) represent standard 1st-line options for advanced non-small cell lung …
New PD-L1 inhibitors in non-small cell lung cancer–impact of atezolizumab
N Seetharamu, IR Preeshagul… - Lung Cancer: Targets …, 2017 - Taylor & Francis
The era of immunotherapy has changed the face of how we approach treatment for many
oncologic and hematologic malignancies. Lung cancer has been in the forefront of …
oncologic and hematologic malignancies. Lung cancer has been in the forefront of …
First-line cemiplimab monotherapy and continued cemiplimab beyond progression plus chemotherapy for advanced non-small-cell lung cancer with PD-L1 50% or …
M Özgüroğlu, S Kilickap, A Sezer, M Gümüş… - The Lancet …, 2023 - thelancet.com
Background Cemiplimab provided significant survival benefit to patients with advanced non-
small-cell lung cancer with PD-L1 tumour expression of at least 50% and no actionable …
small-cell lung cancer with PD-L1 tumour expression of at least 50% and no actionable …